STOCKWATCH: Battle r-oil
This article was originally published in Scrip
The swing in Amarin's fortunes continue, from the highs of an FDA approval to the lows of whether the drug will ever be marketed. The most recent blow to the Irish drug developer was announced on Thanksgiving Day when most of Amarin's investors were away from their offices but the acquisition of Norwegian company Pronova by BASF may be another reason why the marketing battle of prescription fish oil products in cardiovascular indications may never occur.
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.